By Tosin Ola, RN, BSN, MBA-HCM, Founder & President, Sickle Cell Warriors Foundation. Aisha has become the first patient in the United Kingdom to complete gene-editing therapy for sickle cell disease — and is now living without sickle cell crises. This milestone, reported by Manchester University NHS Foundation Trust, matters far beyond one hospital. For decades, families living with sickle cell disease have heard that a cure was distant, experimental, or out of reach. A completed gene-editing treatment, with a patient now living crisis-free, turns that conversation from possibility into proof. Gene-editing therapies such as Casgevy work by editing a patient’s own blood stem cells so the body can produce healthy red blood cells. They are not simple, and they are not yet available to everyone who needs them — access, cost, and eligibility remain real barriers that our community must continue to advocate on. But today, we pause to honour what this means: a life no longer defined by crises, hospital stays, and pain that interrupts school, work, and family. At Sickle Cell Warriors Foundation, we will continue to share trusted research news, advocate for equitable access to curative therapies, and support warriors and caregivers through every step of treatment decisions. What does a milestone like this mean to you and your family? Share your thoughts with our warrior family — your voice helps shape the advocacy ahead. Source: Manchester University NHS Foundation Trust, October 23, 2026: https://mft.nhs.uk/2026/10/23/first-patient-in-the-uk-to-receive-gene-editing-therapy-for-sickle-cell-completes-treatment/
